Ropinirole involved in a fatal case: blood and urinary concentrations.
Amantadine
Fatal blood and urinary concentrations
LC–MS/MS
Parkinson's disease
Ropinirole
Journal
Forensic toxicology
ISSN: 1860-8965
Titre abrégé: Forensic Toxicol
Pays: Japan
ID NLM: 101315563
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
26
04
2021
accepted:
20
06
2021
entrez:
1
12
2022
pubmed:
2
12
2022
medline:
6
12
2022
Statut:
ppublish
Résumé
Ropinirole is an antiparkinsonian drug and has recently been suggested to be effective in amyotrophic lateral sclerosis. It is expected that ropinirole prescriptions will increase in the near future. However, the fatal concentration in blood is unclear at this time. Therefore, we report a fatal case involving ropinirole intoxication and discuss the fatal concentrations with reference to several autopsy cases involving ropinirole. Ropinirole was quantified in femoral vein blood, cardiac blood, and urine from five autopsy cases in which ropinirole was detected by drug screening in our laboratory. One is a ropinirole intoxication case (this report) and the others were non-intoxication cases. Their ropinirole concentrations were compared and discussed. The ropinirole concentration in this case was 100 ng/mL in femoral blood, 160 ng/mL in cardiac blood, and 1840 ng/mL in urine. The ropinirole concentrations in the four non-ropinirole poisoning cases were 7-35 ng/mL (mean: 24 ng/mL) in femoral blood, 13-100 ng/mL (mean: 60 ng/mL) in cardiac blood, and 140-1090 ng/mL (mean: 640 ng/mL) in urine. Cardiac/peripheral ratios were in the range of 1.6-2.1 (mean 1.8). There were no obvious signs of overdose, and the high cardiac/peripheral blood ratio suggested that postmortem redistribution may have occurred, but the peripheral blood ropinirole concentration (100 ng/mL) was obviously higher than that reported in the previous fatal case of ropinirole poisoning (64 ng/mL). Based on these results, the cause of death in this case was considered to be shock and fatal arrhythmia due to ropinirole poisoning. This case provides important data on postmortem blood and urinary levels of ropinirole poisoning.
Identifiants
pubmed: 36454487
doi: 10.1007/s11419-021-00593-8
pii: 10.1007/s11419-021-00593-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-179Informations de copyright
© 2021. Japanese Association of Forensic Toxicology.
Références
Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188:1157–1165. https://doi.org/10.1503/cmaj.151179 (open access article)
doi: 10.1503/cmaj.151179
pubmed: 27221269
pmcid: 5088077
Delamarre A, Meissner WG (2017) Epidemiology, environmental risk factors and genetics of Parkinson’s disease. Presse Med 46:175–181. https://doi.org/10.1016/j.lpm.2017.01.001 (open access article)
doi: 10.1016/j.lpm.2017.01.001
pubmed: 28189372
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global regional and national incidence, prevalence and years lived with disability for 310 disease and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602. https://doi.org/10.1016/S0140-6736(16)31678-6001 (open access article)
doi: 10.1016/S0140-6736(16)31678-6001
Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM, Parkinson’s Foundation P4 Group (2018) Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis 4:21. https://doi.org/10.1038/s41531-018-0058-0 (open access article)
doi: 10.1038/s41531-018-0058-0
pubmed: 30003140
pmcid: 6039505
Vidaihlet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y (1990) Ropinirole without levodopa in Pakinson’s disease. Lancet 336:316–317. https://doi.org/10.1016/0140-6736(90)91855-5
doi: 10.1016/0140-6736(90)91855-5
Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C (2008) Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23:2267–2302. https://doi.org/10.1002/mds.22254 (open access article)
doi: 10.1002/mds.22254
pubmed: 18925578
Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, Okano H (2018) Modeling sporadic ALS in IPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 24:1579–1589. https://doi.org/10.1038/s41591-018-0140-5
doi: 10.1038/s41591-018-0140-5
pubmed: 30127392
Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, Nakahara J (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis–protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther 11:143–166. https://doi.org/10.1016/j.reth.2019.07.002 (open access article)
doi: 10.1016/j.reth.2019.07.002
pubmed: 31384636
pmcid: 6661418
Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S (2020) Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci 41:99–109. https://doi.org/10.1016/j.tips.2019.12.002 (open access article)
doi: 10.1016/j.tips.2019.12.002
pubmed: 31926602
Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908–1910. https://doi.org/10.1212/wnl.52.9.1908
doi: 10.1212/wnl.52.9.1908
pubmed: 10371546
Duband S, Bidat C, Gaillard Y, Rochet M, Camdessanche JP, Péoc’h M (2012) A fatal intoxication case involving ropinirole. J Forensic Leg Med 19:422–425. https://doi.org/10.1016/j.jflm.2012.04.013
doi: 10.1016/j.jflm.2012.04.013
pubmed: 22920767
Simkó J, Szentandrássy N, Harmati G, Bárándi L, Horváth B, Magyar J, Bányász T, Lórincz I, Nánási PP (2010) Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes. Naunyn Schmied Arch Pharmacol 382:213–220. https://doi.org/10.1007/s00210-010-0538-1
doi: 10.1007/s00210-010-0538-1
Di Giacopo R, Fasano A, Fenici R, Loria G, Bentivoglio AR (2010) Rare and serious cardiac side effects during ropinirole titration. Mov Disord 25:1509–1510. https://doi.org/10.1002/mds.23115
doi: 10.1002/mds.23115
pubmed: 20629152
Nagasawa S, Saka K, Yamagishi Y, Yajima D, Chiba F, Yamaguchi R, Torimitsu S, Iwase H (2021) Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors. Leg Med 48:101815. https://doi.org/10.1016/j.legalmed.2020.101815
doi: 10.1016/j.legalmed.2020.101815
Usui K, Hayashizaki K, Hashiyada M, Funayama M (2012) Rapid drug extraction from human whole blood using a modified QuEChERS extraction method. Leg Med 14:286–296. https://doi.org/10.1016/j.legalmed.2012.04.008
doi: 10.1016/j.legalmed.2012.04.008
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (2018) Bioanalytical method validation: guidance for industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf . Accessed 24 May 2018
Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson’s disease. Parkinsonism Relat Disord 15:351–353. https://doi.org/10.1016/j.parkreldis.2008.08.005 (open access article)
doi: 10.1016/j.parkreldis.2008.08.005
pubmed: 18823813
Sande MA, Mandell GL (1980) Antimicrobial agents, chap 54. In: Goodman and Gilman’s the pharmacological basic of therapeutic, 6th edn. Macmillan Publishers, New York, p 1241
Schulz M, Schmoldt A, Andersen-Streichert H, Iwersen-Bergmann S (2020) Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 24:195. https://doi.org/10.1186/s13054-020-02915-5 (open access article)
doi: 10.1186/s13054-020-02915-5
pubmed: 32375836
pmcid: 7201985
Dalpe-Scott M, Degouffe M, Garbutt D, Drost M (1955) A comparison of drug concentrations in postmortem cardiac and peripheral blood in 320 cases. Can Soc Sci J 28:113–121. https://doi.org/10.1080/00085030.1995.10757474
doi: 10.1080/00085030.1995.10757474
Tompson DJ, Vearer D (2007) Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease. Clin Ther 29:2654–2666. https://doi.org/10.1016/j.clinthera.2007.12.010
doi: 10.1016/j.clinthera.2007.12.010
pubmed: 18201581
Hattori N, Hasegawa K, Sakamoto T (2012) Pharmacokinetics and effect of food after oral administration of prolonged release tablets of ropinirole hydrochloride in Japanese patients with Parkinson’s disease. J Clin Pharm Ther 37:571–577. https://doi.org/10.1111/j.1365-2710.2012.01336.x
doi: 10.1111/j.1365-2710.2012.01336.x
pubmed: 22390368
Perea E, Robbins BV, Hutto B (2006) Psychosis related to ropinirole. Am J Psychiatry 163:547–548. https://doi.org/10.1176/appi.ajp.163.3.547
doi: 10.1176/appi.ajp.163.3.547
pubmed: 16513886
Navacerrada F, González-Alonso MR, Alonso-Navarro H, Pilo-de-la-Fuente B, Plaza-Nieto JF, Jiménez-Jiménez FJ (2011) Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome. Eur J Neurol 18:e65. https://doi.org/10.1111/j.1468-1331.2010.03317.x
doi: 10.1111/j.1468-1331.2010.03317.x
pubmed: 21199184
Mannelli M, Lazzeri C, Ianni L, La Villa G, Pupilli C, Bellini F, Serio M, Franchi F (1997) Dopamine and sympathoadrenal activity in man. Clin Exp Hypertens 19:163–179. https://doi.org/10.3109/10641969709080813
doi: 10.3109/10641969709080813
pubmed: 9028644
Yeh T-L, Yang Y-K, Chiu N-T, Yao W-J, Yeh S-J, Wu J-S, Chuang J-I, Chang SH (2006) Correlation between striatal dopamine D
doi: 10.1016/j.amjhyper.2006.03.005
pubmed: 16942941
Hurst RS, Higdon NR, Lawson JA, Clark MA, Rutherford-Root KL, McDonald WG, Haas JV, McGrath JP, Meglasson MD (2003) Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol 482:31–37. https://doi.org/10.1016/j.ejphar.2003.09.054
doi: 10.1016/j.ejphar.2003.09.054
pubmed: 14660002
Humphrey SJ, Turman CN, Curry JT, Wheeler GJ (2006) Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. J Cardiovasc Pharmacol 47:337–347. https://doi.org/10.1097/01.fjc.0000205983.05771.f5
doi: 10.1097/01.fjc.0000205983.05771.f5
pubmed: 16633074
Baselt RC (2017) Disposition of toxic drugs and chemicals in man, 11th edn. Biomedical Publications, Seal Beach, p 1805